JB Chemicals And Pharmaceuticals Growth Triggered By Exclusivity

J.B. Chemicals and Pharmaceuticals Limited (JBCPL) has evolved into a rapidly growing pharmaceutical company, specialising in hypertension treatments.

- 

While the majority of its revenue is generated in India, the company has successfully expanded its presence in key markets like Russia and South Africa. With six brands among the top 300 IPM brands in India, JBCPL has a global footprint, exporting formulations to over 40 countries, including the USA.

Renowned for its expertise in medicated lozenges, JBCPL ranks among the top five manufacturers globally in both medicated and herbal lozenges. The company operates eight cutting-edge manufacturing facilities in India, maintaining stringent quality standards certified by global regulatory authorities.

Revenue Break-Up for Q2FY24 and H1FY24

Internationally, the company has a diverse operational model, with a direct presence in Russia and South Africa, distributor relationships in the U.S., and a leading position in the contract manufacturing market. With over 40 global regulatory accreditations, JBCPL ensures quality across its 10+ dosage forms. In terms of capital expenditure, the company invested approximately `93 crore in H1FY24, primarily for expanding the lozenges manufacturing facility. The estimated capex for the fiscal year is `145 crore, reflecting a commitment to continuous growth.

Moreover, JBCPL’s strategic move into the ophthalmology segment was marked by a trademark license agreement with Novartis Innovative Therapies AG and an exclusive promotion and distribution agreement with Novartis Healthcare Private Limited, signalling a new venture set to commence in January 2027 with a financial commitment of approximately `125 crore.